Daniel Barenboim, Parkinson's disease
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...
Onapgo is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with advanced disease ...
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
Sharon Osbourne, his wife, told The Sun her husband’s voice is still up to the task of performing.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results